New WHO Public Assessment Report (WHOPAR) published
M
Newly Prequalified Active Pharmaceutical Ingredients (APIs)
M
Artemether (WHOAPI-268) manufactured by Chongqing Holley Wuling Mountain Pharmaceutical Co Ltd and Darunavir (ethanolate) (WHOAPI-214) ma
11th Invitation to Manufacturers of Reproductive Health Medicines to submit and Expression of Interest (EOI) for Product Evaluation by the WHO Expert Review Panel (ERP) for Reproductive Health Medicines
M
The lack of prequalified reproductive health medicines is of great concern to WHO and to partner organizations working to improve reproductive health.
The Medicines Patent Pool and Pharco Pharmaceuticals Sign Licence for Promising Hepatitis C Drug Candidate Ravidasvir
M
Agreement seeks to improve health options for hepatitis C patients in low- and middle-income countries.
Ajanta's artemether/lumefantrine tablet range prequalified
M
WHO Prequalification Team - Medicines (PQT) added the below new products to its prequalified list
Cipla's atazanavir/ritonavir tablet prequalified
M
WHO Prequalification Team - Medicines (PQT) added the below new products to its prequalified list
Micro Labs' ethionamide tablet prequalified
M
WHO Prequalification Team - Medicines (PQT) added the below new products to its prequalified list
WHO prequalifies first generic active ingredient for hepatitis C medicines
M
On 31 March 2017, WHO for the first time prequalified a generic active pharmaceutical ingredient (API) for hepatitis C – sofosbuvir.
4th Invitation to manufacturers and suppliers of medicinal products for treatment of hepatitis B and C to submit an expression of interest for product evaluation (EOI)
M
The following products were added:
- Sofosbuvir/Velpatasvir tablet 400mg/100mg
- Velpatasvir tablet 100mg